“`html
WHO Alert: Falsified IBRANCE (Palbociclib) Detected in Multiple Countries
Table of Contents
The world Health Institution (WHO) has issued a medical product alert regarding nine lots of falsified IBRANCE (palbociclib). These substandard products have been identified in Côte d’Ivoire, Egypt, Lebanon, Libya, and Türkiye, and were initially reported to the WHO in November 2025. The falsified IBRANCE is being distributed directly to consumers through online platforms and has also been found in pharmacies [WHO Medical Product Alert].
What is IBRANCE (Palbociclib)?
IBRANCE (palbociclib) is a prescription medication used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. It belongs to a class of drugs called cyclin-dependent kinase (CDK) inhibitors, which work by slowing down the growth of cancer cells [National cancer Institute – palbociclib]. It’s crucial for patients to receive genuine medication to ensure effective treatment and avoid potential harm.
The Risk of Falsified Medicines
Falsified medicines, also known as counterfeit drugs, pose a meaningful threat to public health. They may contain incorrect ingredients, the wrong dosage of the active ingredient, or harmful substances. Using falsified medicines can lead to treatment failure, adverse health effects, and even death. The WHO estimates that 10% of medicines in low- and middle-income countries are substandard or falsified.
Details of the falsified IBRANCE Lots
The WHO alert identifies nine specific lots of falsified IBRANCE. Details regarding the batch numbers and expiry dates can be found on the official WHO alert page [WHO Medical Product Alert]. It is vital for patients, healthcare professionals, and regulatory authorities to be aware of these details to identify and remove the falsified products from circulation.
How to Identify Falsified Medicines
Identifying falsified medicines can be challenging. though, some red flags include:
- Unusually low prices
- Packaging defects or damage
- Incorrect labeling or spelling errors
- Lack of a valid manufacturer’s address
- suspicious online sources
What to Do If you Suspect Falsified IBRANCE
If you suspect you have obtained falsified IBRANCE, do not use it. Report it promptly to your healthcare provider and the national medicines regulatory authority in your country. The WHO encourages all stakeholders to increase vigilance and report any suspected falsified medical products.
Key Takeaways
- Nine lots of falsified IBRANCE (palbociclib) have been identified in multiple countries.
- Falsified medicines pose a serious risk to patient health.
- Patients should only obtain IBRANCE from legitimate sources.
- Report any suspected falsified medicines to healthcare professionals and regulatory authorities.
The WHO continues to monitor the situation and provide updates as they become available. Increased international collaboration and robust regulatory oversight are essential to combat the growing threat of falsified medicines
Keep reading